However, we noted a modest increase in differentiation markers (CD11b, CD14, CD16, and CD38) on the cell surfaces of the primary AML samples after 7 days of EZH2 inhibition (Supplemental Figure S2). Here, CD38 is linked to acute myeloid leukemia.